VXRT Vaxart, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 72444 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.3%
TTM net income YoY157.3%
TTM EPS YoY—
Revenue 3-yr CAGR252.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin16.6%
Net margin16.0%
FCF margin17.6%
EBITDA margin19.3%
Returns
ROE62.4%
ROA16.3%
ROIC (approx.)143.3%
Asset turnover1.02x
Leverage & solvency
Liabilities / assets55.3%
Debt / equity0.00x
Current ratio1.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.13x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.62M | $27.18M | $39.23M | $104.24M | $72.41M | $39.73M | $20.88M | $15.19M |
| R&D expense | $22.83M | $33.75M | $29.41M | $45.15M | $75.95M | $49.73M | $30.74M | $22.65M |
| SG&A expense | $5.07M | $6.60M | $4.64M | $3.67M | $4.28M | $4.60M | $5.07M | $4.02M |
| Operating income | -$17.28M | -$13.17M | $5.17M | $55.42M | -$7.81M | -$14.60M | -$14.94M | -$11.49M |
| Pretax income | -$17.38M | -$13.46M | $5.21M | $55.39M | -$8.12M | -$14.97M | -$15.50M | -$11.81M |
| Income tax | $312,000 | $29,000 | $29,000 | $344,000 | $17,000 | $20,000 | $95,000 | $176,000 |
| Net income | -$17.69M | -$13.49M | $5.18M | $55.05M | -$8.14M | -$14.99M | -$15.59M | -$11.98M |
| EBITDA | -$16.48M | -$12.37M | $6.30M | $57.48M | -$6.91M | -$13.70M | -$12.69M | -$9.26M |
| EPS (basic) | -0.07 | -0.06 | 0.02 | — | -0.04 | -0.07 | -0.07 | — |
| EPS (diluted) | — | — | 0.02 | — | — | — | -0.07 | — |
| Weighted avg. shares (diluted) | — | — | 242.18M | — | — | — | 227.92M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $35.12M | $50.93M | $50.75M | $53.81M | $16.88M | $20.11M | $28.70M | $25.23M |
| Short-term investments | $30.43M | $13.05M | $10.28M | $9.99M | $11.91M | $6.16M | $13.24M | $26.49M |
| Receivables | $21.03M | $11,000 | $7.14M | $14.56M | $42.72M | $4.28M | $1.50M | $5.76M |
| Current assets | $126.43M | $116.69M | $131.70M | $136.12M | $117.37M | $70.38M | $62.65M | $68.26M |
| PP&E, net | $5.01M | $5.50M | $4.83M | $5.43M | $6.06M | $6.93M | $7.82M | $8.71M |
| Goodwill | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M |
| Intangibles | $2.28M | $2.46M | $2.64M | $2.83M | $3.01M | $3.19M | $3.38M | $3.56M |
| Total assets | $148.18M | $165.19M | $180.06M | $186.08M | $208.99M | $164.09M | $158.56M | $166.39M |
| Current liabilities | $73.93M | $73.11M | $76.84M | $86.75M | $169.30M | $117.88M | $98.50M | $90.88M |
| Total liabilities | $81.89M | $82.81M | $85.94M | $98.28M | $182.23M | $131.21M | $112.94M | $107.46M |
| Shareholders' equity | $66.29M | $82.37M | $94.12M | $87.80M | $26.76M | $32.88M | $45.62M | $58.92M |
| Shares outstanding | 243.70M | 242.84M | 241.41M | 240.49M | 228.96M | 228.91M | 228.22M | 227.77M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.43M | $2.78M | -$2.05M | $30.66M | $2.60M | -$15.95M | -$9.60M | -$7.34M |
| Capital expenditure | $371,000 | $35,000 | $448,000 | $1,000 | $117,000 | -$103,000 | $130,000 | $44,000 |
| Free cash flow | $1.06M | $2.74M | -$2.50M | $30.66M | $2.48M | -$15.84M | -$9.73M | -$7.39M |
| Investing cash flow | -$17.66M | -$2.72M | -$676,000 | $1.99M | -$5.82M | $7.23M | $13.23M | $10.40M |
| Financing cash flow | $411,000 | $121,000 | -$338,000 | $4.28M | -$4,000 | $125,000 | -$164,000 | $136,000 |
| Depreciation & amortization | $800,000 | $800,000 | $1.13M | $2.06M | $900,000 | $900,000 | $2.25M | $2.24M |
| Stock-based compensation | $1.19M | $1.29M | $1.48M | $1.72M | $2.02M | $2.12M | $2.46M | $2.35M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.